Year All20242023202220212020201920182017201620152014 Abivax Completes Enrolment of Phase IIa Clinical Trial of ABX464 to Treat Patients with Ulcerative Colitis May 14, 2018 Read More ABIVAX announces the publication of its 2018 Registration Document April 30, 2018 Read More ABIVAX Strengthens its Management Team with the Appointment of Alexandra Pearce, Ph.D. as Vice President of Regulatory Affairs April 09, 2018 Read More 2017 Full-Year Results and Progress Report March 16, 2018 Read More ABIVAX Upcoming Events March 12, 2018 Read More ABIVAX Appoints Carol L. Brosgart, M.D. to its Board of Directors January 29, 2018 Read More ABIVAX to Initiate Long-Term Extension Study of ABX464 in Patients with Ulcerative Colitis January 04, 2018 Read More ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018 December 21, 2017 Read More ABIVAX’s ABX464 Phase IIa Data confirm HIV Reservoir Reduction in Oral Presentation at 8th International Workshop on HIV Persistence During Therapy December 15, 2017 Read More ABIVAX to present in plenary session at the 8th international conference on HIV persistence during therapy December 07, 2017 Read More
Abivax Completes Enrolment of Phase IIa Clinical Trial of ABX464 to Treat Patients with Ulcerative Colitis May 14, 2018 Read More
ABIVAX Strengthens its Management Team with the Appointment of Alexandra Pearce, Ph.D. as Vice President of Regulatory Affairs April 09, 2018 Read More
ABIVAX to Initiate Long-Term Extension Study of ABX464 in Patients with Ulcerative Colitis January 04, 2018 Read More
ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018 December 21, 2017 Read More
ABIVAX’s ABX464 Phase IIa Data confirm HIV Reservoir Reduction in Oral Presentation at 8th International Workshop on HIV Persistence During Therapy December 15, 2017 Read More
ABIVAX to present in plenary session at the 8th international conference on HIV persistence during therapy December 07, 2017 Read More
